Aliath Bioventures, part of AltamarCAM Partners, is the groups’ life sciences impact investment business. The firm also reinforces the life sciences team with the appointment of Joana Correia as a senior analyst that join Beatriz Gandarias, Jose Maria Fernández and the Alta Life Sciences team Madrid, 19th of September 2023.- Aliath Bioventures, the healthcare impact investment platform of AltamarCAM Partners, appoints Philippe Monteyne, MD, PhD as a new Partner…
This fund specialises in investing in companies in the healthcare sector: biotechnology/biopharma and health technologies (digital health, medical devices and diagnostics). Aliath Bioventures, part of the AltamarCAM group, is a healthcare sector impact investment platform. This is AltamarCAM’s first Article 9 vehicle under the Sustainable Finance Disclosure Regulation (SFDR). Madrid, 14 March 2023.- AltamarCAM Partners, a global asset manager focused on investing in private markets, has registered its new fund ACP Aliath…
New placement program for the binx io, the first and only male/female FDA-cleared, CLIA-waived point-of-care instrument for chlamydia (CT) and gonorrhea (NG), offers CLIA-waived facilities the opportunity to deliver critical CT/NG results in about 30 minutes versus days through centralized lab testing November 01, 2022 08:00 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–binx health, a healthcare technology and women’s health company focused on making routine testing broadly accessible and convenient, announced today the…
Financing led by new investors Innvierte and an undisclosed strategic investor with participation from existing investors Kurma Partners, Alta Life sciences, UI Investissement and Axis BARCELONA, Spain – October 20, 2022 – DeepUll, a medical diagnostics company developing culturefree, affordable diagnostic solutions for the early identification of sepsis and other acute infections, announces today that it has raised €13 million in a Series B financing round. The round was led…
MAFTEST® analyses of the NSABP-B34 and AZURE landmark clinical trials confirmed clinical utility of the MAFTEST® for selection of early-stage breast cancer patients that benefit from adjuvant clodronate treatment. Reduces the risk of death at 5 and 10 years by 26% and 23% respectively. Identifies almost twice as many patients able to benefit from the intervention than are selected using current clinical guidelines. Data published in Annals of Oncology, (33),…
First-in-class peptidomimetic with distinct MoA activating trophic signaling pathways to protect and prevent damage to the optic nerve and retina Potential to be disease modifying in lead indications such as glaucoma, geographic atrophy, acute optic neuritis (AON) and other optic neuropathies Proof of concept (PoC) clinical trial in progress for AON with results due 2H23 Agreement supports Oculis’s mission to become a global ophthalmology leader bringing breakthrough innovations to the…
https://www.expansion.com/catalunya/2022/01/17/61e5cb41468aeb02298b4662.html Peptomyc_Expansion
https://www.businesswire.com/news/home/20211214005380/en/binx-health-Selected-as-a-Top-Digital-Health-Startup-that-is-Transforming-the-Future-of-Healthcare—-Named-to-the-2021-CB-Insights-Digital-Health-150-List
http://mybinxhealth.com/news/binx-health-and-student-health-insurer-wellfleet-expand-agreement-in-college-health-for-in-dorm-and-at-home-access-to-testing-for-sexually-transmitted-infections-(stis)
Seasoned biotech executive with a wealth of experience and a track-record of strategic alliances in the immuno-oncology space Barcelona, Spain, 2 December 2021: ONA Therapeutics (“ONA”), which is focused on the discovery and development of therapeutic biologics targeting lipid metabolism to treat advanced cancer, today announces the appointment of Dr Michel Detheux as Independent Chair to its Board of Directors. Dr Michel Detheux is a veteran biotech executive with 25…
